<DOC>
	<DOC>NCT01082146</DOC>
	<brief_summary>This will be an open-label, non-randomized, absorption, metabolism, and excretion study of Lurasidone administered in a suspension at 40 mg to 6 normal healthy male subjects in a postprandial state</brief_summary>
	<brief_title>RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE</brief_title>
	<detailed_description>A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [Isothiazolyl-3-14C]-Lurasidone Following Postprandial Single Oral Dose Administration in Healthy Male Subjects.</detailed_description>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>1. within a BMI range of 18.0 to 28.0 kg/m2 inclusive; 2. males will either be sterile or agree to use from Checkin until 45 days following Study Completion/Discharge approved methods of contraception 3. able to comprehend and willing to sign an Informed Consent Form (ICF); 4. able to void urine on a daily basis and 1 to 2 bowel movements per day. 5. able to swallow 60 mL of dosing suspension. 1. history or presence of an abnormal ECG 2. participation in more than 1 other radiolabeled investigational study drug trial within 12 months prior to Checkin. 3. exposure to significant radiation within 12 months prior to Checkin; 4. participation in any other investigational study drug trial 5. use of any prescription medications/products within 14 days prior to Checkin 6. use of any inhibitors or inducers of CYP3A4 taken within 30 days prior to Checkin, including but not limited to drugs listed in Appendix E; 7. receipt of blood products within 2 months prior to Checkin;</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>pharmacokinetics, lurasidone</keyword>
</DOC>